ArticleInvestigative ophthalmology & visual science2026
Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to investigate the role of ellagic acid (EA) in alleviating oxidative stress and inflammation in Fuchs endothelial corneal dystrophy (FECD) and to evaluate its therapeutic potential by targeting urokinase-type plasminogen activator (PLAU) and modulating NF-κB signaling. Methods: We integrated bioinformatics analyses using multiple databases to identify EA target genes and FECD-related differentially expressed genes (DEGs), along with functional enrichment. Experimental validation was carried out in H2O2-stimulated and UVA-irradiated human corneal endothelial cell (CEC) line B4G12. Molecular docking, receiver operating characteristic (ROC) analysis, immune infiltration, and siRNA-mediated knockdown were applied to confirm key targets and pathways. Results: Our study identified 1284 EA target genes and 297 FECD-related DEGs, with 21 overlapping genes. From this intersection, a protein-protein interaction (PPI) network identified 10 hub genes. Functional enrichment analysis revealed that these hub genes were significantly associated with key pathways, including NF-κB signaling, inflammatory regulation, and oxidative stress responses. Among these hub genes, PLAU was selected for further investigation due to its key role in the PPI network, its strong correlation with immune cell infiltration, and its high diagnostic value (area under the curve [AUC] = 0.933). Molecular docking predicted a strong interaction between EA and PLAU. Subsequent in vitro experiments demonstrated that EA treatment attenuates inflammation and oxidative damage by targeting PLAU and modulating the NF-κB signaling in CECs. Conclusions: These findings demonstrate that EA alleviates oxidative stress and inflammation in FECD by targeting PLAU and regulating NF-κB signaling. This study supports the therapeutic potential of EA and PLAU as a novel intervention for corneal endothelial diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.